



uniQure to Participate in Multiple Upcoming Industry Conferences in October

September 27, 2019

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in October:

- **2019 Cantor Global Healthcare Conference, October 2 – 4, New York City.**
 - [Matt Kapusta](#), chief executive officer at uniQure, will present a corporate update on Wednesday, October 2, at 9:30 a.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.
- **2019 Cell & Gene Meeting on the Mesa, October 2 – 4, Carlsbad, California.**
 - [Jonathan Garen](#), chief business officer at uniQure, will participate in a panel discussion "Cell and Gene Therapy for Neurological Product Indications" on Wednesday October 2, at 4:00 p.m. PT.
 - Mr. Garen also will present a corporate update on Wednesday, October 2, at 2:45 p.m. PT.
- **National Hemophilia Foundation 71st Bleeding Disorders Conference, October 3 – 5, Anaheim, California.**
 - uniQure will deliver the following presentations during the conference:
 - **Title:** *No Evidence of Germline Transmission of Vector DNA Following Intravenous Administration of AAV5-hFIX to Male Mice*
Abstract number: CRA21
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT
 - **Title:** *AMT-061 (AAV5-Padua hFIX variant) an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Follow-up up to 9 Months in a Phase 2b trial*
Abstract number: QOL29
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT
 - **Title:** *An Evaluation of Health Utility and Quality-of-Life in Hemophilia: A Systematic Literature Review*
Presentation date: Friday, October 4
Presentation time: 5:15 – 6:15 p.m. PT
- **European Huntington Association 2019 Conference, October 4 – 6, Bucharest, Romania.**
 - Melvin Evers, Ph.D., associate director research at uniQure, will be presenting on the Company's gene therapy candidate AMT-130 for Huntington's disease on Sunday October 6, at 10:30 a.m. CET.
 - Dr. Evers will also participate in a panel discussion at the conclusion of the presentation session "Drug Trials in Huntington's Disease: What is Happening Right Now?" at 11:20 a.m. CET.
- **Chardan 3rd Annual Genetic Medicines Conference, October 7 – 8, New York City**
 - Matt Kapusta will participate in a fireside chat with research analyst Gbola Amusa on Tuesday, October 8, at 11:00 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.
- **European Society for Gene and Cell Therapy 2019 Collaborative Congress, October 22 – 25, Barcelona, Spain.**
 - uniQure will deliver the following presentations during the conference:
 - **Title:** *A Novel AAV-Based miQURE Gene Therapy for Spinocerebellar Ataxia Type 3*

Abstract number: P247

Presentation date: Wednesday, October 23

Presentation time: 1:00 – 2:30 p.m. CET

- **Title:** *Stem Cell Derived Brain Organoids, a Promising Model to Study Adeno Associated Viruses for CNS Gene Therapy*

Abstract number: P381

Presentation date: Wednesday, October 23

Presentation time: 1:00 – 2:30 p.m. CET

- **Title:** *Prevalence and Affinity/Avidity Assessment of Pre-Existing NABs Against AAV2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors*

Abstract number: P336

Presentation date: Thursday, October 24

Presentation time: 1:00 – 2:30 p.m. CET

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a [pipeline](#) of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

Maria E. Cantor

Direct: 339-970-7536

Eva M. Mulder

Direct: +31 20 240 6103

FOR MEDIA:

Tom Malone

Direct: 339-970-7558